Cellares: Funding, Investors & Team (Sep 2026)

Cellares develops the Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit. The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope. Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources and is difficult to scale. Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively, and at the scale they need. The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates, and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.

Cellares has raised $339M across 2 rounds on record. The most recent is a Series D of $257M announced in Jan 2026.

Cellares' most recent funding round on record is a Series D of $257M, announced in Jan 2026.

Fabian Gerlinghaus is listed as CEO at Cellares.

Cellares is based in South San Francisco, California, United States.

Cellares is in the 11-50 employee band.

Cellares' latest round of $257M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.